Activity Overview
Biomarker-driven advancements, including immune checkpoint inhibitors and antibody-drug conjugates targeting HER2 and TROP2, have provided critical options for patients with endometrial cancer. However, disparities in access have meant these advancements do not reach all patients who might benefit from them.
In this spotlight symposium, presented at the 17th Annual International Symposium on Gynecologic Malignancies, case-based discussions explore epidemiology, inequalities, and current and emerging immunotherapy options for patients with endometrial cancer. Expert faculty provide invaluable clinical pearls and practical strategies to help learners apply trial data to the clinical setting.
This educational activity is an archive
of the live virtual symposium held on May 9, 2026.
Target Audience
This educational activity is directed toward oncologists,
gynecologists, nurses, nurse practitioners, physician assistants, and other health
care professionals involved in the diagnosis and treatment of endometrial
cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the evidence for contemporary and emerging biomarker testing strategies in individualizing therapy for patients with endometrial cancer
- Evaluate recent clinical trial data for the use of biomarker-driven therapies in advanced and recurrent endometrial cancer
- Apply shared decision-making strategies to develop personalized treatment plans that reflect molecular findings, patient goals, and access considerations
Kathleen N. Moore, MD, MS, FASCO
Gynecologic Oncologist, Deputy Director
Fred and Pamela Buffett Cancer Center
University of Nebraska
Omaha, NE
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AADI Bioscience, AbbVie, AstraZeneca, BeOne Medicines, BioNTech, Corcept Therapeutics, Daiichi Sankyo, DualityBio, GSK, ImmunoGen, Incyte, Janssen, Loxo/Eli Lilly and Company, Merck, Pfizer, PMV Pharma, Regeneron, Schrödinger, Verastem Oncology, Whitehawk Therapeutics, Zymeworks; Grant/Research Funding: Allarity Therapeutics, AstraZeneca, Daiichi Sankyo, GSK, Immunocore, Iovance Biotherapeutics, Regeneron, Schrödinger, Verastem Oncology; Royalty or Patent Benefits: UpToDate; Other: American Society of Clinical Oncology Board of Directors
Ritu Salani, MD, MBA
Director, Division of Gynecologic Oncology
Professor, Department of Obstetrics and Gynecology
University of California, Los Angeles
Los Angeles, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Daiichi Sankyo, Eisai, Genmab, Merck, Whitehawk; Royalty or Patent Benefits: UpToDate
Casey Cosgrove, MD
Physician, Associate Professor
Gynecologic Oncology
The Ohio State University Comprehensive Cancer Center
Columbus, OH
Disclosures: Advisor, Consultant, Fee for Service Recipient: AbbVie, Daiichi Sankyo, GSK, Merck; Grant/Research Funding: Regeneron
Ebony R. Hoskins, MD, FACOG
Section Director, Gynecologic Oncology
MedStar Washington Hospital Center
Assistant Professor of Clinical Obstetrics and Gynecology
Georgetown University Medical Center
Washington, DC
Disclosures: Ebony R. Hoskins, MD, FACOG, has no relevant financial relationships with ineligible companies.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Additional Disclaimers
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only. It is not intended to substitute for the independent clinical judgment of a health care professional regarding diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.
In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.
Learners are encouraged to independently evaluate the information
presented and apply their own clinical judgment when considering patient care
decisions.